Featured news from NHIVNA
HIV-related news from NAM
Abacavir: new studies challenge the evidence of reduced potency when viral load is high
Gus Cairns, 2012-11-26 07:50:00
An analysis of two studies of the new HIV integrase inhibitor dolutegravir presented at the Eleventh International Congress on Drug Therapy in HIV Infection in Glasgow had the incidental effect of bringing into question evidence from a previous study that suggested that the NRTI (nucleoside reverse transcriptase inhibitor) drug abacavir was less potent in people starting HIV therapy with high viral loads than another NRTI drug, tenofovir.
Source:1
